Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442038 · ClinicalTrials.gov registry record · Phase 3
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,651
- Enrollment target
NCT01442038: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT01442038 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 2,651 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (243% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01442038, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,651 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.
Primary Outcome
Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,651 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
What the finished NCT01442038 record still lists
NCT01442038 is an interventional study that assigns participants to a tested intervention. Its 2,651 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (243% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01442038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01442038 about?
NCT01442038 is a clinical study titled "Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)". This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia...
What is the current status of trial NCT01442038?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,651 participants. The study started on 2011-10. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01442038?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01442038?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01442038's enrollment target sits among peer trials
2,651 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06825715 · 2,653 participants · NA
Multilevel Intervention for Precision Oncology
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
- NCT05471908 · 2,674 participants · NA
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia